Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming in ...

Ariel Investments, an investment management company, released its “Ariel Focus Fund" Q1 2026 Investor Letter. A copy of the ...

Have you looked into how Bio-Rad Laboratories (BIO) performed internationally during the quarter ending March 2026? Considering the widespread global presence of this maker of instruments used in ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...

New PTC Harmony Thermal Cycler Line Expands Access to Reliable, High-Performance PCR Across Academic and Biopharma ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...

Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

On Thursday Congress held the first of a series of planned hearings on the recent — and some might say reckless — proliferation of high-security bio-laboratories in the U.S. The questions at hand: How ...